150322-43-3 | 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4H,5H,6H,7H-thieno[3,2-c]pyridin-2-yl acetate

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$6.00	$4.00
25mg	98%	in stock	$8.00	$6.00
1g	98%	in stock	$55.00	$38.00
5g	98%	in stock	$251.00	$176.00
10g	98%	in stock	$387.00	$271.00
25g	98%	in stock	$760.00	$532.00

Description

• Catalog Number: AA75638
• Chemical Name: 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4H,5H,6H,7H-thieno[3,2-c]pyridin-2-yl acetate
• CAS Number: 150322-43-3
• Molecular Formula: C20H20FNO3S
• Molecular Weight: 373.4411
• MDL Number: MFCD09954140
• SMILES: CC(=O)Oc1sc2c(c1)CN(CC2)C(c1ccccc1F)C(=O)C1CC1

Computed Properties

• Complexity: 555
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 26
• Hydrogen Bond Acceptor Count: 6
• Rotatable Bond Count: 6
• Undefined Atom Stereocenter Count: 1
• XLogP3: 3.6

Literature

• Toxicity of thienopyridines on human neutrophil granulocytes and lymphocytes.

  Toxicology 20130607

• The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.

  Drugs 20121112

• Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial.

  Clinical science (London, England : 1979) 20121101

• Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention.

  Journal of thrombosis and thrombolysis 20121101

• The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.

  PharmacoEconomics 20121101

• [Platelet inhibitors in clinical practice].

  Therapeutische Umschau. Revue therapeutique 20121101

• Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.

  The New England journal of medicine 20121004

• Current antiplatelet options for NSTE-ACS patients.

  QJM : monthly journal of the Association of Physicians 20121001

• Prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction.

  Cardiovascular drugs and therapy 20121001

• Breaking resistance: is there still a reason for clopidogrel in acute STEMI? : editorial to: 'prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction' by D. Alexopoulos et al.

  Cardiovascular drugs and therapy 20121001

• New anti-platelet agents: the end of resistance?

  Thrombosis research 20121001

• Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.

  Circulation. Cardiovascular interventions 20121001

• Identification of a promising drug candidate for the treatment of type 2 diabetes based on a P2Y(1) receptor agonist.

  Journal of medicinal chemistry 20120913

• Switching patients from clopidogrel to prasugrel in acute coronary syndrome: effects of prasugrel loading dose on residual platelet reactivity.

  Journal of thrombosis and haemostasis : JTH 20120901

• Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.

  The American journal of medicine 20120901

• Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?

  Thrombosis and haemostasis 20120901

• UA/NSTEMI: Are you following the latest guidelines?

  Nursing 20120901

• TRITON and beyond: new insights into the profile of prasugrel.

  Cardiovascular therapeutics 20120801

• Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)?

  Current cardiology reports 20120801

• Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions.

  Thrombosis and haemostasis 20120801

• Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel.

  Expert opinion on pharmacotherapy 20120801

• [Removal of epidural catheter under dual antiplatelet therapy following acute coronary syndrome : scenario without special consideration to the current guidelines on epidural regional anesthesia].

  Der Anaesthesist 20120801

• Failure of high-dose clopidogrel in recurrent stent thrombosis.

  Singapore medical journal 20120801

• Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.

  Journal of the American College of Cardiology 20120731

• Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.

  Journal of the American College of Cardiology 20120717

• Quantitative comparison of clopidogrel 600 mg, prasugrel and ticagrelor, against clopidogrel 300 mg on major adverse cardiovascular events and bleeding in coronary stenting: synthesis of CURRENT-OASIS-7, TRITON-TIMI-38 and PLATO.

  International journal of cardiology 20120712

• Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats.

  Thrombosis research 20120701

• Prasugrel during primary percutaneous coronary intervention: evidence from clinical data.

  Current vascular pharmacology 20120701

• Advances in antiplatelet therapy for acute coronary syndromes.

  Postgraduate medical journal 20120701

• Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.

  Clinical pharmacokinetics 20120701

• Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel.

  Biopharmaceutics & drug disposition 20120701

• Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.

  Journal of the American College of Cardiology 20120619

• Allergic reaction to prasugrel and cross-reactivity with clopidogrel.

  International journal of cardiology 20120614

• Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.

  Journal of medicinal chemistry 20120614

• A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.

  Journal of the American College of Cardiology 20120612

• Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy.

  Journal of clinical pharmacology 20120601

• Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse.

  Thrombosis and haemostasis 20120601

• Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20120601

• Meeting new challenges with antiplatelet therapy in primary care.

  The Journal of family practice 20120601

• [Platelet function: new drugs, new assays : possible impacts on operative medicine?].

  Der Anaesthesist 20120601

• Metabolic activation of prasugrel: nature of the two competitive pathways resulting in the opening of its thiophene ring.

  Chemical research in toxicology 20120521

• Pharmacodynamic effects of prasugrel dosing regimens in patients on maintenance prasugrel therapy: results of a prospective randomized study.

  Journal of the American College of Cardiology 20120508

• Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.

  Lancet (London, England) 20120505

• High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study.

  European heart journal 20120501

• Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention.

  Thrombosis research 20120501

• Unstable angina and non-ST elevation myocardial infarction.

  American journal of respiratory and critical care medicine 20120501

• Toward a therapeutic window for antiplatelet therapy in the elderly.

  European heart journal 20120501

• A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention.

  Clinical pharmacology and therapeutics 20120501

• Using models to predict the future: what to do when the data run out?

  Clinical pharmacology and therapeutics 20120501

• CYP2C19 genotype-guided antiplatelet therapy in a patient with clopidogrel resistance.

  Connecticut medicine 20120501

• Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.

  Expert review of clinical pharmacology 20120501

• Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent.

  Journal of medicinal chemistry 20120412

• New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment.

  Journal of gastroenterology and hepatology 20120401

• Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20120401

• Cost is not a barrier to implementing clopidogrel pharmacogenetics.

  Pharmacotherapy 20120401

• Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.

  Pharmacotherapy 20120401

• Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.

  Hospital practice (1995) 20120401

• Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world.

  International journal of cardiology 20120322

• A case of acute stent thrombosis during treatment with the thrombopoietin receptor agonist peptide--romiplostim.

  Heart, lung & circulation 20120301

• Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.

  Pharmacotherapy 20120301

• Acute coronary syndromes: identifying the appropriate patient for prasugrel.

  Postgraduate medicine 20120301

• Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.

  JACC. Cardiovascular interventions 20120301

• The illusion of 'optimal' platelet inhibition.

  JACC. Cardiovascular interventions 20120301

• Electrospray ionization LC-MS/MS validated method for the determination of the active metabolite (R-138727) of prasugrel in human plasma and its application to a bioequivalence study.

  Drug testing and analysis 20120201

• Pharmacokinetic basis of the antiplatelet action of prasugrel.

  Fundamental & clinical pharmacology 20120201

• Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel.

  Current medical research and opinion 20120201

• P2Y12 platelet inhibition in clinical practice.

  Journal of thrombosis and thrombolysis 20120201

• Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel.

  Thrombosis and haemostasis 20120201

• A comprehensive comparative review of adenosine diphosphate receptor antagonists.

  Expert opinion on pharmacotherapy 20120201

• InforMatrix: ADP antagonists in acute coronary syndromes.

  Expert opinion on pharmacotherapy 20120201

• 'Conversations in cardiology': How do you pick the best antiplatelet drug--clopidogrel, prasugrel, ticagrelor for your PCI patient?

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20120201

• Desensitization to prasugrel: cardiology's increased need for allergy consultation.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20120201

• Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BAsel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design.

  American heart journal 20120201

• Rationale and design of the TAXUS Libertē Post-Approval Study: examination of patients receiving the TAXUS Liberté stent with concomitant prasugrel therapy in routine interventional cardiology practice.

  American heart journal 20120201

• Prasugrel as a safe alternative for clopidogrel-induced polyarthralgias.

  Pharmacotherapy 20120201

• American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38).

  Circulation 20120131

• Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel.

  The American journal of cardiology 20120115

• Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.

  British journal of clinical pharmacology 20120101

• Prasugrel resistance: fact or fiction.

  Platelets 20120101

• Evaluation of the INNOVANCE PFA P2Y test cartridge: sensitivity to P2Y(12) blockade and influence of anticoagulant.

  Platelets 20120101

• Cost-effectiveness of prasugrel in a US managed care population.

  Journal of medical economics 20120101

• RAPID GENE trial marks the validation of the first point-of-care genetic test in clinical medicine.

  Pharmacogenomics 20120101

• New antiplatelet and anticoagulant drugs.

  General dentistry 20120101

• [Optimal antiplatelet and antithrombotic therapy in patients with ST elevation myocardial infarction].

  Kardiologia polska 20120101

• [Letter to Kardiologia Polska concerning optimal treatment of myocardial infarction].

  Kardiologia polska 20120101

• Current oral antiplatelets: focus update on prasugrel.

  Journal of the American Board of Family Medicine : JABFM 20120101

• [New antithrombotic drugs].

  Duodecim; laaketieteellinen aikakauskirja 20120101

• Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor.

  Platelets 20120101

• Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agent.

  International journal of toxicology 20120101

• Antiplatelet therapy beyond 2012: role of personalized medicine.

  Polskie Archiwum Medycyny Wewnetrznej 20120101

• [Prasugrel].

  Hamostaseologie 20120101

• [Comparative antiplatelet efficacy of prasugrel and high-dose clopidogrel in patients with coronary heart disease including acute coronary syndrome].

  Kardiologiia 20120101

• Clopidogrel in coronary artery disease: update 2012.

  Advances in cardiology 20120101

• Prasugrel.

  Advances in cardiology 20120101

• Genetic considerations.

  Advances in cardiology 20120101

• Advances in the monitoring of anti-P2Y12 therapy.

  Platelets 20120101

• Thienopyridines and other ADP-receptor antagonists.

  Handbook of experimental pharmacology 20120101

• Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices.

  BMJ case reports 20120101

• Rate of nuisance bleedings and impact on compliance to prasugrel in acute coronary syndromes.

  The American journal of cardiology 20111215

• Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity.

  Journal of thrombosis and haemostasis : JTH 20111201

• Novel use of prasugrel for intracranial stent thrombosis.

  Journal of neurointerventional surgery 20111201

• Prasugrel and bivalirudin for primary angioplasty: early results on stent thrombosis and bleeding.

  International journal of cardiology 20111201

• Platelet function profiles in the elderly: results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity.

  Thrombosis and haemostasis 20111201

• Successful use of prasugrel, an alternative antiplatelet agent, in a patient with clopidogrel allergy.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20111201

• Platelet-mediated thrombosis and drug-eluting stents.

  Circulation. Cardiovascular interventions 20111201

• Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease.

  Journal of the American College of Cardiology 20111122

• Triple therapy in hospitalized patients: facts and controversies.

  Journal of hospital medicine 20111101

• Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients.

  Metabolism: clinical and experimental 20111101

• Drug-drug interactions in HIV medicine: a not so simple and straightforward road to the future.

  Metabolism: clinical and experimental 20111101

• Direct vasoactive properties of thienopyridine-derived nitrosothiols.

  Journal of cardiovascular pharmacology 20111101

• Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro.

  The Journal of pharmacology and experimental therapeutics 20111101

• Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor.

  Current medical research and opinion 20111101

• Antiplatelet options for secondary prevention in acute coronary syndromes.

  Expert review of cardiovascular therapy 20111101

• Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI.

  Clinical research in cardiology : official journal of the German Cardiac Society 20111001

• Prevalence of contraindications and conditions for precaution for prasugrel administration in a real world acute coronary syndrome population.

  Journal of thrombosis and thrombolysis 20111001

• Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel.

  Journal of thrombosis and haemostasis : JTH 20111001

• Genotypic and phenotypic assessment of platelet function and response to P2Y12 antagonists.

  Current cardiology reports 20111001

• Antiplatelet effects of aspirin vary with level of P2Y₁₂ receptor blockade supplied by either ticagrelor or prasugrel.

  Journal of thrombosis and haemostasis : JTH 20111001

• Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies.

  The American journal of cardiology 20111001

• Use of prasugrel in a patient with clopidogrel hypersensitivity.

  The Annals of pharmacotherapy 20111001

• Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel.

  American heart journal 20111001

• Esophageal mucosal lesion with low-dose aspirin and prasugrel mimics malignancy: a case report.

  World journal of gastroenterology 20110921

• Ticagrelor (Brilinta)--better than clopidogrel (Plavix)?

  The Medical letter on drugs and therapeutics 20110905

• [Multiple arterial thrombosis and resistance to conventional antiaggregation].

  Revista espanola de cardiologia 20110901

• Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes.

  European heart journal 20110901

• Selective blockade of P2Y12 receptors by prasugrel inhibits myocardial infarction induced by thrombotic coronary artery occlusion in rats.

  Journal of cardiovascular pharmacology 20110901

• Massive thrombus burden with recurrence of intracoronary thrombosis early after stenting and delayed onset of prasugrel action in a patient with ST-elevation myocardial infarction and cardiac shock.

  Thrombosis and haemostasis 20110901

• Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy.

  American heart journal 20110901

• Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes.

  International journal of cardiology 20110804

• Anti-platelet treatments in acute coronary syndrome: simplified network meta-analysis.

  International journal of cardiology 20110804

• Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation).

  Current atherosclerosis reports 20110801

• Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS?

  Current cardiology reports 20110801

• Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44.

  Thrombosis and haemostasis 20110801

• Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?

  Wiener klinische Wochenschrift 20110801

• Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndrome.

  Hospital practice (1995) 20110801

• High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes.

  Journal of the American College of Cardiology 20110726

• Current status and prospects of antiplatelet therapy in percutaneous coronary intervention in Japan: focus on adenosine diphosphate receptor inhibitors.

  Journal of cardiology 20110701

• Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials.

  QJM : monthly journal of the Association of Physicians 20110701

• Absence of 'rebound' platelet hyperreactivity following cessation of prasugrel.

  Thrombosis and haemostasis 20110701

• The importance of high-quality evidence of the long-term impact of nonfatal events used in randomized controlled trials: a case study of prasugrel.

  Clinical pharmacology and therapeutics 20110701

• Subacute stent thrombosis owing to complete clopidogrel resistance successfully managed with prasugrel.

  The Journal of invasive cardiology 20110701

• Oral antiplatelet agents clopidogrel and prasugrel for the prevention of cardiovascular events.

  BMJ (Clinical research ed.) 20110617

• Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38).

  Circulation 20110614

• Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor.

  Expert opinion on pharmacotherapy 20110601

• [Myocardial infarction: Role of new antiplatelet agents].

  Presse medicale (Paris, France : 1983) 20110601

• [Update on anti-platelet therapy].

  Deutsche medizinische Wochenschrift (1946) 20110601

• Ticagrelor for acute coronary syndrome?

  Drug and therapeutics bulletin 20110601

• Prasugrel as a safe alternative for clopidogrel-associated arthritis.

  The Journal of invasive cardiology 20110601

• [Specificities of diabetes in acute coronary syndromes].

  Revue medicale suisse 20110601

• [New approaches and indications for the analysis of platelet function in cardiology].

  Hamostaseologie 20110502

• Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate.

  Thrombosis and haemostasis 20110501

• Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors.

  Thrombosis and haemostasis 20110501

• The intestine as an important contributor to prasugrel active metabolite formation in vivo.

  Drug metabolism and disposition: the biological fate of chemicals 20110401

• A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.

  European heart journal 20110401

• [Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?].

  Deutsche medizinische Wochenschrift (1946) 20110401

• [Do genetic factors reduce the effects of clopidogrel?].

  Deutsche medizinische Wochenschrift (1946) 20110401

• Triple therapy: boon or bane for high-risk CV patients?

  The Journal of family practice 20110401

• A comparison of prasugrel at the time of percutaneous coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction: design and rationale for the ACCOAST study.

  American heart journal 20110401

• Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.

  JACC. Cardiovascular interventions 20110401

• [Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists].

  Recenti progressi in medicina 20110401

• Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel.

  Clinical therapeutics 20110401

• Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent.

  Journal of clinical pharmacology 20110301

• The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data.

  Journal of cardiovascular pharmacology 20110301

• The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects.

  Blood 20110217

• Oral antiplatelet therapy for the management of acute coronary syndromes: defining the role of prasugrel.

  Critical care nurse 20110201

• Glutaredoxin and thioredoxin can be involved in producing the pharmacologically active metabolite of a thienopyridine antiplatelet agent, prasugrel.

  Drug metabolism and disposition: the biological fate of chemicals 20110201

• A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty.

  Journal of thrombosis and thrombolysis 20110201

• Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.

  Arteriosclerosis, thrombosis, and vascular biology 20110201

• Resistance to anti-platelet agents.

  Thrombosis research 20110201

• [Coronary heart disease - what is of importance after coronary intervention?].

  Deutsche medizinische Wochenschrift (1946) 20110201

• Is prasugrel more effective than clopidogrel at preventing future cardiac events?

  JAAPA : official journal of the American Academy of Physician Assistants 20110201

• Cyphering the statistical and clinical significance of prasugrel in the TRITON-TIMI 38 trial.

  International journal of cardiology 20110121

• Prasugrel as alternative treatment strategy in a case with a hypersensitivity reaction to clopidogrel.

  Platelets 20110101

• Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.

  Thrombosis and haemostasis 20110101

• Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development.

  Expert opinion on investigational drugs 20110101

• Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy.

  BMC medicine 20110101

• Pharmacokinetics, drug metabolism, and safety of prasugrel and clopidogrel.

  Postgraduate medicine 20110101

• Timing of thienopyridine loading and outcomes in the TRITON trial: the FDA Prasugrel Action Package outlook.

  Cardiovascular revascularization medicine : including molecular interventions 20110101

• Prasugrel offers consistent platelet control in appropriate patients requiring treatment.

  Cardiovascular journal of Africa 20110101

• Relative bioavailability of prasugrel free base in comparison to prasugrel hydrochloride in the presence and in the absence of a proton pump inhibitor.

  Arzneimittel-Forschung 20110101

• Prasugrel study addresses timing of thienopyridine loading dose in NSTEMI patients pre-PCI (the ACCOAST study).

  Cardiovascular journal of Africa 20110101

• Prasugrel as an alternative for clopidogrel-associated neutropenia.

  The Canadian journal of cardiology 20110101

• Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview.

  Vascular health and risk management 20110101

• Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity.

  Cardiology journal 20110101

• ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.

  Circulation 20101214

• Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel.

  Clinical pharmacokinetics 20101201

• [Evidence-based management of ST-segment elevation myocardial infarction (STEMI). Latest guidelines of the European Society of Cardiology (ESC) 2010].

  Herz 20101201

• An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention.

  Critical pathways in cardiology 20101201

• Prasugrel: an efficacy and safety review of a new antiplatelet therapy option.

  Critical pathways in cardiology 20101201

• ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use.

  The American journal of gastroenterology 20101201

• Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: balancing safety and efficacy.

  American heart journal 20101201

• [Prasugrel--oral (Efient)].

  Journal de pharmacie de Belgique 20101201

• [Current options to manage clopidogrel poor responsiveness].

  Giornale italiano di cardiologia (2006) 20101201

• Platelet inhibition and cancer promotion.

  Archives of internal medicine 20101122

• Prasugrel and cancer.

  Archives of internal medicine 20101122

• Identification, evaluation and treatment of prasugrel low-response after coronary stent implantation--a preliminary study.

  Thrombosis research 20101101

• A new era for antiplatelet therapy in patients with acute coronary syndrome.

  The American journal of the medical sciences 20101101

• A comparison of the metabolism of clopidogrel and prasugrel.

  Expert opinion on drug metabolism & toxicology 20101101

• Ticagrelor and prasugrel: two novel, most-promising antiplatelet agents.

  Recent patents on cardiovascular drug discovery 20101101

• Price, pragmatism and ∇prasugrel.

  Drug and therapeutics bulletin 20101101

• Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.

  Hospital practice (1995) 20101101

• [Medication of the month. Prasugrel (Efient): potent thienopyridine antiplatelet agent].

  Revue medicale de Liege 20101101

• Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.

  Lancet (London, England) 20101016

• Response to antiplatelet treatment: from genes to outcome.

  Lancet (London, England) 20101016

• State of the art of new P2Y12 antagonists.

  Internal and emergency medicine 20101001

• Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis.

  Atherosclerosis 20101001

• Prasugrel as antiplatelet therapy in patients with acute coronary syndromes or undergoing percutaneous coronary intervention.

  Critical care nurse 20101001

• Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability.

  Current drug metabolism 20101001

• Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study.

  Journal of the American College of Cardiology 20100921

• New antithrombotic agents--insights from clinical trials.

  Nature reviews. Cardiology 20100901

• Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial.

  Current medical research and opinion 20100901

• Controversies in oral antiplatelet therapy in patients undergoing aortocoronary bypass surgery.

  The Annals of thoracic surgery 20100901

• Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention: NICE technology appraisal guidance.

  Heart (British Cardiac Society) 20100901

• Letter by Serebruany regarding article, 'Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38'.

  Circulation 20100824

• Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data.

  Journal of thrombosis and haemostasis : JTH 20100801

• [Platelet inhibition with prasugrel].

  Deutsche medizinische Wochenschrift (1946) 20100801

• Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.

  Cardiovascular drugs and therapy 20100801

• Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy.

  JACC. Cardiovascular interventions 20100801

• Prasugrel.

  Circulation 20100727

• Formation and fate of a sulfenic acid intermediate in the metabolic activation of the antithrombotic prodrug prasugrel.

  Chemical research in toxicology 20100719

• Mortality in the TRITON trial: update from the FDA prasugrel action package.

  The American journal of cardiology 20100715

• The role of antiplatelet therapy in the secondary prevention of coronary artery disease.

  Current opinion in cardiology 20100701

• A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis.

  Journal of cardiovascular pharmacology 20100701

• Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents.

  Current opinion in cardiology 20100701

• Acute coronary syndrome in the patient with diabetes: is the management different?

  Current cardiology reports 20100701

• What goes into a major acute coronary syndrome trial and what will future trials look like?

  Current cardiology reports 20100701

• Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.

  American heart journal 20100701

• [Novel agents in antiplatelet therapy].

  Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 20100701

• Prasugrel and cancer: an uncertain association or a credible risk that meaningfully alters the benefit-risk balance.

  Archives of internal medicine 20100628

• Prasugrel as a potential cancer promoter: review of the unpublished data.

  Archives of internal medicine 20100628

• What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.

  QJM : monthly journal of the Association of Physicians 20100601

• Preventing serious sequelae after an acute coronary syndrome: the consequences of thrombosis versus bleeding with antiplatelet therapy.

  Journal of cardiovascular pharmacology 20100601

• Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite.

  Drug metabolism and disposition: the biological fate of chemicals 20100601

• Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact.

  Nature reviews. Drug discovery 20100601

• The year in interventional cardiology.

  Journal of the American College of Cardiology 20100518

• Advances in antiplatelet treatment for acute coronary syndromes.

  Heart (British Cardiac Society) 20100501

• Mortality in the TRITON trial: update from the FDA prasugrel action package.

  The American journal of cardiology 20100501

• Implementing genotype-guided antithrombotic therapy.

  Future cardiology 20100501

• Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention.

  Health technology assessment (Winchester, England) 20100501

• A potent alternative to clopidogrel emerges. Prasugrel appears to lower heart attack risk for patients with acute coronary syndrome.

  Heart advisor 20100501

• Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.

  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20100401

• [Interview with Prof. Franz-Joseph Krozingen: Interventional cardiology on the success course].

  MMW Fortschritte der Medizin 20100401

• Diabetes and acute coronary syndrome.

  Minerva medica 20100401

• Dosing strategies for antiplatelet therapy in percutaneous coronary intervention.

  Hospital practice (1995) 20100401

• A time for growth.

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20100401

• Thienopyridine antiplatelet agents: focus on prasugrel.

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20100401

• Role of ticagrelor in clopidogrel nonresponders: resistance is futile?

  Circulation 20100316

• Prasugrel, Māori, and personalised medicine in New Zealand.

  The New Zealand medical journal 20100305

• Management of antiplatelet therapy during acute percutaneous coronary intervention: new strategies and therapeutics.

  Annals of the Academy of Medicine, Singapore 20100301

• The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects.

  European journal of clinical pharmacology 20100201

• Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.

  Journal of clinical pharmacology 20100201

• The TRITON versus PLATO trials: differences beyond platelet inhibition.

  Thrombosis and haemostasis 20100201

• Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.

  British journal of pharmacology 20100201

• Lack of outcome benefit and clopidogrel 'resistance.' The TRITON trial challenge.

  Thrombosis and haemostasis 20100201

• Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial.

  Clinical therapeutics 20100201

• [Extent of platelet aggregation inhibition and clinical events: new evidence with prasugrel].

  Giornale italiano di cardiologia (2006) 20100201

• Ticagrelor in ACS: redefining a new standard of care?

  Lancet (London, England) 20100123

• Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.

  Circulation 20100105

• Emerging P2Y12 receptor antagonists: role in coronary artery disease.

  Current vascular pharmacology 20100101

• Interpreting the TRITON results in light of the event adjudication process.

  Cardiology 20100101

• Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.

  Thrombosis and haemostasis 20100101

• Reducing cardiac ischemic events in patients with ACS: prasugrel versus clopidogrel. Commentary.

  Postgraduate medicine 20100101

• Platelet inhibitors: update on clopidogrel (Plavix) and the recently approved prasugrel (Effient).

  General dentistry 20100101

• Trial watch. DAPT study.

  Harvard heart letter : from Harvard Medical School 20100101

• Delays of event adjudication in the TRITON trial.

  Cardiology 20100101

• Prasugrel, a new platelet inhibitor.

  The Mount Sinai journal of medicine, New York 20100101

• Prasugrel: a novel platelet ADP P2Y(12) receptor antagonist.

  Methods in molecular biology (Clifton, N.J.) 20100101

• [Antiplatelet therapy in coronary heart disease. Some problems and achivements].

  Kardiologiia 20100101

• [Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial].

  Kardiologiia 20100101

• Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update.

  Vascular health and risk management 20100101

• Antagonism of P2Y₁₂ reduces physiological thromboxane levels.

  Platelets 20100101

• New antiplatelet agents.

  Acta anaesthesiologica Belgica 20100101

• Antiplatelet therapy in the perioperative period.

  Acta anaesthesiologica Belgica 20100101

• New antiplatelet agents: why they are needed.

  European journal of internal medicine 20091201

• Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?

  Medical science monitor : international medical journal of experimental and clinical research 20091201

• Clopidogrel versus prasugrel: times are changing, but not for everyone.

  Pharmacotherapy 20091201

• Prasugrel: a critical comparison with clopidogrel.

  Pharmacotherapy 20091201

• Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding risk.

  Cleveland Clinic journal of medicine 20091201

• Clinical trial update II: TRITON-TIMI 38 provides reassurance on concomitant use of proton pump inhibitors and thienopyridines.

  European heart journal 20091201

• Prasugrel: a novel antiplatelet therapy for acute coronary syndromes.

  Recent patents on cardiovascular drug discovery 20091101

• Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.

  Thrombosis research 20091101

• A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel.

  Drug metabolism and disposition: the biological fate of chemicals 20091101

• Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel.

  Xenobiotica; the fate of foreign compounds in biological systems 20091101

• Stent thrombosis: who's guilty?

  European heart journal 20091101

• P2Y12 inhibitors: thienopyridines and direct oral inhibitors.

  Hamostaseologie 20091101

• Dual antiplatelet therapy in coronary artery disease: a case-based approach.

  Cleveland Clinic journal of medicine 20091101

• Prasugrel: Clinical development and therapeutic application.

  Advances in therapy 20091101

• Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease.

  Journal of clinical pharmacy and therapeutics 20091001

• Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease.

  Journal of clinical pharmacy and therapeutics 20091001

• Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.

  Prescrire international 20091001

• [Changing times for clopidogrel].

  Medizinische Monatsschrift fur Pharmazeuten 20091001

• Risk of combining PPIs with thienopyridines: fact or fiction?

  Lancet (London, England) 20090919

• Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.

  Lancet (London, England) 20090919

• Ticagrelor--is there need for a new player in the antiplatelet-therapy field?

  The New England journal of medicine 20090910

• Challenges in oral antiplatelet therapy: ST-segment elevation myocardial infarction.

  The American journal of cardiology 20090907

• Prasugrel (Effient) vs. clopidogrel (Plavix).

  The Medical letter on drugs and therapeutics 20090907

• Prasugrel in clinical practice.

  The New England journal of medicine 20090903

• Weighing benefits and risks--the FDA's review of prasugrel.

  The New England journal of medicine 20090903

• [New thrombocyte inhibitor. Fewer ischemic complications in acute coronary syndrome].

  MMW Fortschritte der Medizin 20090903

• Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.

  Pharmacotherapy 20090901

• Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.

  American heart journal 20090901

• Prasugrel: a review of its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention.

  Drugs 20090820

• Cardiovascular disease gets personal.

  Nature 20090820

• The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.

  Journal of the American College of Cardiology 20090818

• The Italian Horizon Scanning Project.

  European journal of clinical pharmacology 20090801

• Aggressive chronic platelet inhibition with prasugrel and increased cancer risks: revising oral antiplatelet regimens?

  Fundamental & clinical pharmacology 20090801

• Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects.

  Current medical research and opinion 20090801

• Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38.

  Journal of clinical pharmacology 20090801

• Prediction of prasugrel active metabolite concentrations from 2 downstream inactive metabolite concentrations using multilinear regression analysis.

  Journal of clinical pharmacology 20090801

• P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.

  European heart journal 20090801

• Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects.

  Platelets 20090801

• Test before you stop.

  Archives of surgery (Chicago, Ill. : 1960) 20090801

• Prasugrel, new platelet inhibitor, subject of formulary debates.

  Managed care (Langhorne, Pa.) 20090801

• Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.

  European heart journal 20090701

• Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.

  European heart journal 20090701

• New P2Y12 blockers.

  Journal of thrombosis and haemostasis : JTH 20090701

• Letter by Rosenstein and Parra regarding article, 'Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel: Thrombolysis in Myocardial Infarction 38'.

  Circulation 20090630

• Effects of prasugrel, a novel P2Y(12) inhibitor, in rat models of cerebral and peripheral artery occlusive diseases.

  European journal of pharmacology 20090610

• Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction.

  Circulation 20090602

• Can we override clopidogrel resistance?

  Circulation 20090602

• Management of patients with high gastrointestinal risk on antiplatelet therapy.

  Gastroenterology clinics of North America 20090601

• Prasugrel.

  Nature reviews. Drug discovery 20090601

• Future of oral antiplatelet therapy: four challenged hypotheses.

  Thrombosis and haemostasis 20090601

• Review of prasugrel for the secondary prevention of atherothrombosis.

  Journal of managed care pharmacy : JMCP 20090601

• Pharmacy benefit spending poised to increase for antithrombotic drug therapy -- prasugrel versus clopidogrel.

  Journal of managed care pharmacy : JMCP 20090601

• Diabetes and acute coronary syndromes.

  Best practice & research. Clinical endocrinology & metabolism 20090601

• Prasugrel STEMI subgroup analysis.

  Lancet (London, England) 20090530

• Prasugrel STEMI subgroup analysis.

  Lancet (London, England) 20090530

• Prasugrel STEMI subgroup analysis.

  Lancet (London, England) 20090530

• Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.

  Circulation 20090519

• Bedside evaluation of thienopyridine antiplatelet therapy.

  Circulation 20090519

• Platelet inhibition with prasugrel and increased cancer risks: potential causes and implications.

  The American journal of medicine 20090501

• New antiplatelet drugs: beyond aspirin and clopidogrel.

  International journal of clinical practice 20090501

• Critical review of prasugrel for formulary decision makers.

  Journal of managed care pharmacy : JMCP 20090501

• Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention.

  Future cardiology 20090501

• Update on oral antiplatelet therapy: principles, problems and promises.

  Future cardiology 20090501

• Novel antiplatelet strategies in acute coronary syndromes.

  Cleveland Clinic journal of medicine 20090401

• Response variability and the role of platelet function testing.

  The Journal of invasive cardiology 20090401

• Adjunctive Pharmacotherapy Part II.

  The Journal of invasive cardiology 20090401

• Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.

  Expert review of cardiovascular therapy 20090401

• Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel.

  Drug metabolism and disposition: the biological fate of chemicals 20090301

• Facts and controversies of aspirin and clopidogrel therapy.

  American heart journal 20090301

• Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin.

  American heart journal 20090301

• Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.

  Critical pathways in cardiology 20090301

• Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs.

  Xenobiotica; the fate of foreign compounds in biological systems 20090301

• Ischaemia versus bleeding: the art of clinical decision-making.

  Lancet (London, England) 20090227

• Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.

  Lancet (London, England) 20090227

• [American Heart Association conference 2008. The JUPITER trial, the approval of prasugrel, the (aging) heart of obese adolescents].

  Revue medicale suisse 20090225

• Advances in antiplatelet therapy: agents in clinical development.

  The American journal of cardiology 20090202

• Prasugrel for arterial coronary thrombosis.

  Drugs of today (Barcelona, Spain : 1998) 20090201

• [Cardiology].

  Revue medicale suisse 20090114

• P2Y12 inhibitors in cardiovascular disease: focus on prasugrel.

  The Annals of pharmacotherapy 20090101

• Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials.

  Expert review of cardiovascular therapy 20090101

• Another view on prasugrel.

  Thrombosis and haemostasis 20090101

• Prasugrel development - claims and achievements.

  Thrombosis and haemostasis 20090101

• Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.

  Thrombosis and haemostasis 20090101

• Current problems, new opportunities and future directions of anti-platelet therapy - increasing role of novel antiplatelet agents in cardiovascular diseases.

  Recent patents on cardiovascular drug discovery 20090101

• The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.

  Postgraduate medicine 20090101

• Novel antiplatelet agents in development: prasugrel, ticagrelor, and cangrelor and beyond.

  American journal of therapeutics 20090101

• Prasugrel for the treatment of patients with acute coronary syndrome.

  Vascular health and risk management 20090101

• Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel.

  Vascular health and risk management 20090101

• The FDA prasugrel review: adjudication of myocardial infarction controversy.

  Cardiology 20090101

• Late prasugrel benefit in STEMI patients?

  American journal of therapeutics 20090101

• Relevance of metabolic activation pathways: the example of clopidogrel and prasugrel.

  Arzneimittel-Forschung 20090101

• [Pharmazie in unserer Zeit 4/2009].

  Pharmazie in unserer Zeit 20090101

• [Prodrug activation as a crucial difference. Prasugrel - a new ADP receptor antagonist].

  Pharmazie in unserer Zeit 20090101

• [Technological and biopharmaceutical aspects. Antiplatelet agents for oral administration].

  Pharmazie in unserer Zeit 20090101

• Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial.

  Reviews in cardiovascular medicine 20090101

• Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20090101

• Prasugrel: a novel platelet ADP P2Y receptor antagonist.

  Cardiovascular therapeutics 20090101

• Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial.

  Drugs & aging 20090101

• Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

  Vascular health and risk management 20090101

• Prasugrel hydrochloride, dronedarone, and saxagliptin hydrochloride.

  Journal of the American Pharmacists Association : JAPhA 20090101

• New advances and new questions in cardiovascular therapeutics.

  American journal of therapeutics 20090101

• Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice?

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20090101

• Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.

  Journal of the American College of Cardiology 20081209

• The pursuit of clinically relevant measures of platelet function after antiplatelet drug therapy.

  Journal of the American College of Cardiology 20081209

• Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.

  Nature clinical practice. Cardiovascular medicine 20081201

• Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.

  Journal of pharmacokinetics and pharmacodynamics 20081201

• Modulation of clopidogrel pharmacodynamic response.

  Pharmacotherapy 20081201

• Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects.

  Pharmacotherapy 20081201

• Is prasugrel more effective than clopidogrel in patients with acute coronary syndrome scheduled for PCI?

  American family physician 20081201

• Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor.

  Journal of thrombosis and haemostasis : JTH 20081101

• Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?

  Cardiology clinics 20081101

• Prasugrel: a novel platelet ADP P2Y12 receptor antagonist. A review on its mechanism of action and clinical development.

  Expert opinion on pharmacotherapy 20081101

• Future prospects in anti-platelet therapy: a review of potential P2Y12 and thrombin receptor antagonists.

  Recent patents on cardiovascular drug discovery 20081101

• Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.

  Circulation 20081014

• Acute coronary syndromes and diabetes mellitus: a winning ticket for prasugrel.

  Circulation 20081014

• Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial.

  European heart journal 20081001

• Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease.

  Thrombosis and haemostasis 20081001

• Intensive antiplatelet therapy for reduction of ischaemic events.

  Lancet (London, England) 20080816

• Intensive antiplatelet therapy for reduction of ischaemic events.

  Lancet (London, England) 20080816

• Pharmacology of emerging novel platelet inhibitors.

  American heart journal 20080801

• Clinical profile of prasugrel, a novel thienopyridine.

  American heart journal 20080801

• Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion.

  Journal of interventional cardiology 20080801

• Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.

  Current medical research and opinion 20080801

• The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2.

  Drug metabolism and disposition: the biological fate of chemicals 20080701

• The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function.

  Journal of thrombosis and haemostasis : JTH 20080701

• Antiplatelet therapy in acute coronary syndromes.

  Current cardiology reports 20080701

• For better or for worse: the future of antiplatelet therapy.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080601

• Prasugrel: a novel antiplatelet agent.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080601

• Multiple electrode aggregometry and P2Y(12) antagonists.

  Thrombosis and haemostasis 20080601

• Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.

  Platelets 20080601

• Antiplatelet drugs in cardiological practice: established strategies and new developments.

  Vascular health and risk management 20080601

• Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.

  Journal of the American College of Cardiology 20080527

• Excess rates of nonfatal myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel (preventing clinical events or chasing enzymatic ghosts?).

  The American journal of cardiology 20080501

• A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38.

  The American journal of cardiology 20080501

• Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.

  Lancet (London, England) 20080419

• Approaching an age of reason with antiplatelet therapy.

  Lancet (London, England) 20080419

• Will prasugrel supersede clopidogrel for acute coronary syndromes?

  The Medical journal of Australia 20080407

• Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.

  Journal of clinical pharmacology 20080401

• Prasugrel versus clopidogrel.

  The New England journal of medicine 20080320

• Prasugrel versus clopidogrel.

  The New England journal of medicine 20080320

• Prasugrel versus clopidogrel.

  The New England journal of medicine 20080320

• The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.

  Platelets 20080301

• Prasugrel, a third generation thienopyridine and potent platelet inhibitor.

  Current opinion in investigational drugs (London, England : 2000) 20080301

• [The TRITON-TIMI 38 trial].

  Giornale italiano di cardiologia (2006) 20080301

• [Prasugrel versus clopidogrel. From the American Heart Association meeting, 2007].

  Revue medicale suisse 20080213

• The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities.

  Journal of thrombosis and haemostasis : JTH 20080201

• The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.

  Thrombosis and haemostasis 20080201

• [Commentary to the article: Wiviott S D, Braunwald E, McCabe C H et al. Prasugrel versus clopidogrel in patients with acute coronary syndrome. N Engl J Med 2007; 357: 2001-15].

  Kardiologia polska 20080201

• Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.

  European journal of pharmacology 20080128

• Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.

  European heart journal 20080101

• Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans.

  Journal of clinical pharmacology 20080101

• A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.

  Thrombosis and haemostasis 20080101

• Bleeding risks with prasugrel in the TRITON trial: good news ... bad news.

  Cardiology 20080101

• Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger.

  Cerebrovascular diseases (Basel, Switzerland) 20080101

• [Prasugrel versus Clopidogrel in patients with acute coronary syndromes. Results of the TRITON-TIMI 38 trial].

  Kardiologiia 20080101

• Prasugrel: a new antiplatelet drug for the prevention and treatment of cardiovascular disease.

  Cardiology in review 20080101

• Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine.

  Drug metabolism and pharmacokinetics 20080101

• Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.

  Circulation 20071218

• Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.

  Journal of thrombosis and haemostasis : JTH 20071201

• [Prasugrel, a new thienopyridine].

  Hamostaseologie 20071201

• Prasugrel versus clopidogrel in patients with acute coronary syndromes.

  The New England journal of medicine 20071115

• Intensifying platelet inhibition--navigating between Scylla and Charybdis.

  The New England journal of medicine 20071115

• Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.

  Journal of cardiovascular pharmacology 20071101

• The influence of P2Y12 receptor deficiency on the platelet inhibitory activities of prasugrel in a mouse model: evidence for specific inhibition of P2Y12 receptors by prasugrel.

  Biochemical pharmacology 20071001

• Antiplatelet agents make a comeback in ST-elevation myocardial infarction.

  American heart journal 20071001

• Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis.

  Journal of cardiovascular pharmacology and therapeutics 20070901

• Disposition and metabolic fate of prasugrel in mice, rats, and dogs.

  Xenobiotica; the fate of foreign compounds in biological systems 20070801

• Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status.

  The American journal of cardiology 20070715

• The disposition of prasugrel, a novel thienopyridine, in humans.

  Drug metabolism and disposition: the biological fate of chemicals 20070701

• The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite.

  Journal of thrombosis and haemostasis : JTH 20070701

• The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin.

  Thrombosis and haemostasis 20070701

• New antiplatelet therapies for acute coronary syndromes.

  Current cardiology reports 20070701

• Absorption, distribution and excretion of the new thienopyridine agent prasugrel in rats.

  Xenobiotica; the fate of foreign compounds in biological systems 20070701

• Stereoselective metabolism of prasugrel in humans using a novel chiral liquid chromatography-tandem mass spectrometry method.

  Drug metabolism and disposition: the biological fate of chemicals 20070601

• Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.

  Clinical pharmacology and therapeutics 20070501

• A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans.

  British journal of clinical pharmacology 20070401

• Thienopyridines in cardiovascular disease: focus on clopidogrel resistance.

  Thrombosis and haemostasis 20070301

• Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects.

  Journal of cardiovascular pharmacology 20070301

• Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20070101

• A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.

  American heart journal 20070101

• Platelet P2 receptors: old and new targets for antithrombotic drugs.

  Expert review of cardiovascular therapy 20070101

• ADP receptor antagonism: what's in the pipeline?

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20070101

• Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.

  Cardiovascular drug reviews 20070101

• Prasugrel.

  Expert opinion on investigational drugs 20061201

• Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).

  American heart journal 20061001

• Aspirin and clopidogrel resistance: consideration and management.

  Journal of interventional cardiology 20061001

• Prasugrel, clopidogrel, and combining Swedish apples with American oranges.

  European heart journal 20060801

• Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial.

  International journal of clinical practice 20060701

• Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study.

  Postgraduate medical journal 20060601

• Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans.

  Platelets 20060601

• Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans.

  Platelets 20060601

• Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.

  European heart journal 20060501

• Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.

  Drug metabolism and disposition: the biological fate of chemicals 20060401

• The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects.

  Journal of cardiovascular pharmacology 20060301

• Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.

  Thrombosis and haemostasis 20050901

• Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.

  Circulation 20050628

• Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.

  Seminars in thrombosis and hemostasis 20050401

• Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747.

  British journal of pharmacology 20010101